As the new week unfolds, earnings and economic data will again dictate sentiment.
Aurinia plans to slash 45% of its entire workforce with an aim to save more than $40 million in annual operating expenses.
The biotech's premium valuation doesn't seem to be sitting well with investors.
The biotech's board is exploring strategic alternatives to boost shareholder value.
September S&P 500 futures (ESU23) are trending up +0.33% this morning as market participants awaited a reading on the Federal Reserve’s preferred inflation gauge.
MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial...
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for first quarter ended March 31, 2023. Amounts are expressed in U.S. dollars.
MKT Capital Ltd. (together with its affiliates, “MKT Capital” or “we”), a significant shareholder of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) with beneficial...